Related Experiment Video
Updated: Jun 29, 2025
08:53
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
10.0K
Primary Cutaneous Diffuse Large B-cell Lymphoma Successfully Treated With R-CHOP Chemotherapy
Wafa M Alghamdi1, Fawaz H Aljehani1, Abdullah M Alharthi1
1Dermatology, King Abdulaziz Hospital, Makkah, SAU.
Cureus
|April 1, 2024
Summary
Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) is an aggressive skin cancer. A case report shows successful treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
Area of Science:
- Dermatology
- Oncology
- Hematology
Background:
- Primary cutaneous diffuse large B-cell lymphomas (PCDLBCLs) are a subset of cutaneous B-cell lymphomas, accounting for 10%-20% of cases.
- These lymphomas typically manifest as skin nodules and are characterized by rapid growth and a poor prognosis.
Observation:
- This article details a case of PCDLBCL presenting as a rapidly enlarging skin lesion on the right cheek.
- Diagnosis was confirmed through clinicopathological assessment and specific immunohistochemical markers.
Findings:
- The patient received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
- An 11-month follow-up revealed significant clinical improvement with no signs of extracutaneous spread or disease recurrence.
Implications:
- This case highlights the efficacy of R-CHOP chemotherapy in managing PCDLBCL.
- Effective treatment can lead to favorable outcomes, even in aggressive presentations of this rare skin lymphoma.
